Purpose
|
Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.
|
Characteristics
|
Tradename: Ceritinib Target: TGF-beta/Smad inhibitor, IGF-1R inhibitor Receptor: ALK,IR, IGF-1R Status: JAN,USAN, USP
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
100?%
|
Formula
|
C28H36ClN5O3S
|
Solubility
|
DMSO > 10mM
|